|
|
Volumn 11, Issue 10, 2010, Pages 910-911
|
|
Imatinib treatment of metastatic GIST: Don't stop (believing)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD34 ANTIGEN;
HERMES ANTIGEN;
IMATINIB;
SALINOMYCIN;
ANTINEOPLASTIC AGENT;
BENZAMIDE DERIVATIVE;
PIPERAZINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PYRIMIDINE DERIVATIVE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER CONTROL;
CANCER STEM CELL;
CANCER SURVIVAL;
CELL DIFFERENTIATION;
CELL POPULATION;
CELL PROLIFERATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG TARGETING;
GASTROINTESTINAL STROMAL TUMOR;
HUMAN;
INTERSTITIAL CELL OF CAJAL;
METASTASIS POTENTIAL;
MONOTHERAPY;
NOTE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT DURATION;
TREATMENT RESPONSE;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
DRUG ADMINISTRATION;
GASTROINTESTINAL NEOPLASMS;
MINIMAL RESIDUAL DISEASE;
MORTALITY;
MULTICENTER STUDY (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK ASSESSMENT;
RISK FACTOR;
SECONDARY;
TIME;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
DRUG ADMINISTRATION SCHEDULE;
GASTROINTESTINAL NEOPLASMS;
HUMANS;
MULTICENTER STUDIES AS TOPIC;
NEOPLASM, RESIDUAL;
PIPERAZINES;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
RISK FACTORS;
TIME FACTORS;
TREATMENT OUTCOME;
BENZAMIDES;
|
|
EID: 77957367410
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(10)70225-4 Document Type: Note |
|
Times cited : (9)
|
|
References (6)
|
